Camurus AB (publ) (STO:CAMX)
448.00
+10.60 (2.42%)
Mar 25, 2026, 3:19 PM CET
Camurus AB Revenue
In the year 2025, Camurus AB had annual revenue of 2.27B SEK with 21.30% growth. Camurus AB had revenue of 464.46M in the quarter ending December 31, 2025, a decrease of -16.03%.
Revenue
2.27B
Revenue Growth
+21.30%
P/S Ratio
11.54
Revenue / Employee
7.95M
Employees
285
Market Cap
26.13B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.27B | 397.80M | 21.30% |
| Dec 31, 2024 | 1.87B | 150.73M | 8.78% |
| Dec 31, 2023 | 1.72B | 760.51M | 79.52% |
| Dec 31, 2022 | 956.34M | 355.77M | 59.24% |
| Dec 31, 2021 | 600.57M | 264.57M | 78.74% |
| Dec 31, 2020 | 336.00M | 230.39M | 218.16% |
| Dec 31, 2019 | 105.61M | 56.28M | 114.12% |
| Dec 31, 2018 | 49.32M | -4.99M | -9.18% |
| Dec 31, 2017 | 54.31M | -59.43M | -52.25% |
| Dec 31, 2016 | 113.74M | -41.06M | -26.53% |
| Dec 31, 2015 | 154.80M | -53.41M | -25.65% |
| Dec 31, 2014 | 208.21M | 10.49M | 5.31% |
| Dec 31, 2013 | 197.72M | 102.51M | 107.68% |
| Dec 31, 2012 | 95.20M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioArctic AB | 2.00B |
| Saniona AB | 434.40M |
| BioInvent International AB | 226.50M |
| Hansa Biopharma AB | 222.27M |
| Genovis AB (publ.) | 129.65M |
| Egetis Therapeutics AB | 62.40M |
| Medivir AB | 8.50M |
| Xspray Pharma AB | 6.43M |
Camurus AB News
- 4 months ago - Camurus reports positive topline results for CAM2056, semaglutide monthly depot - PRNewsWire
- 10 months ago - Camurus' POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients - PRNewsWire
- 10 months ago - Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins - PRNewsWire
- 11 months ago - CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU - PRNewsWire
- 1 year ago - US FDA declines to approve Camurus' rare hormone disorder drug - Reuters
- 1 year ago - New publication shows effectiveness data for weekly and monthly buprenorphine injections in treating opioid dependence in individuals using fentanyl - PRNewsWire